Victor Adorno Febles

Victor Adorno Febles

Auto-generated profile, based on publicly available information

Victor Adorno Febles

Department of Medicine, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in JCO Precision Oncology
Verified
Journal Article
Closed access
DWDavid R. Wise
David R. Wise
JSJeffrey A. Schneider
Jeffrey A. Schneider
JAJoshua Armenia
Joshua Armenia
VFVictor Adorno Febles
Victor Adorno Febles
BMBridget McLaughlin
Bridget McLaughlin
FTfor the International SU2C/PCF Prostate Cancer Dream Team
for the International SU2C/PCF Prostate Cancer Dream Team
PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) with low androgen receptor (AR) and without neuroendocrine signaling, termed double-negative prostate cancer (DNPC), is increasingly prevalent in patients treated with AR signaling inhibitors and is in need of new biomarkers and therapeutic targets. METHODS: Candidate genes enriched in DNPC were determined using differential gene expression analysis of discovery and validation cohorts of mCRPC biopsies. Laboratory studies were carried out in human mCRPC organoid cultures, prostate cancer (PCa) cell lines, and mouse xenograft models. Epigenetic studies were carried out in a rapid autopsy cohort. RESULTS: Dickkopf-1 (DKK1) expression is increased in DNPC relative to prostate-specific antigen (PSA)–expressing mCRPC in the Stand Up to Cancer/Prostate Cancer Foundation discovery cohort (11.2 v 0.28 reads per kilobase per million mapped reads; q < 0.05; n = 117) and in the University of Washington/Fred Hutchinson Cancer Research Center cohort (9.2 v 0.99 fragments per kilobase of transcript per million mapped reads; P < .0001). DKK1 expression can be regulated by activated Wnt signaling in vitro and correlates with activating canonical Wnt signaling mutations and low PSA mRNA in mCRPC biopsies ( P < .05). DKK1 hypomethylation was associated with increased DKK1 mRNA expression (Pearson r = −0.66; P < .0001) in a rapid autopsy cohort (n = 7). DKK1-high mCRPC biopsies are infiltrated with significantly higher numbers of quiescent natural killer (NK) cells ( P < .005) and lower numbers of activated NK cells ( P < .0005). Growth inhibition of the human PCa model PC3 by the anti-DKK1 monoclonal antibody DKN-01 depends on the presence of NK cells in a severe combined immunodeficient xenograft mouse model. CONCLUSION: These results support DKK1 as a contributor to the immunosuppressive tumor microenvironment of DNPC. These data have provided the rationale for a clinical trial targeting DKK1 in mCRPC (ClinicalTrials.gov identifier: NCT03837353 ).

29 March 2023 in The Prostate
Verified
Journal Article
Closed access
VFVictor R. Adorno Febles
Victor R. Adorno Febles
YHYuan Hao
Yuan Hao
AAAarif Ahsan
Aarif Ahsan
JWJiansheng Wu
Jiansheng Wu
YQYingzhi Qian
Yingzhi Qian
DWDavid R. Wise
David R. Wise

12 May 2022 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
NSNeil J Shah
Neil J Shah
VPVaibhav Patel
Vaibhav Patel
XZXiaobo Zhong
Xiaobo Zhong
LPLuis Pina
Luis Pina
JHJessica E Hawley
Jessica E Hawley
WOWilliam Oh
William Oh
TMPRSS2, a cell surface protease regulated by androgens and commonly upregulated in prostate cancer (PCa), is a necessary component for SARS-CoV-2 viral entry into respiratory epithelial cells. Previous reports suggested a lower risk of SARS-CoV-2 among PCa patients on androgen deprivation therapy (ADT). However, the impact of ADT on severe COVID-19 illness is poorly understood. We performed a multicenter study across 7 US medical centers and evaluated patients with PCa and SARS-CoV-2 detected by polymerase-chain-reaction between March 1, 2020, and May 31, 2020. PCa patients were considered on ADT if they had received appropriate ADT treatment within 6 months of COVID-19 diagnosis. We used multivariable logistic and Cox proportional-hazard regression models for analysis. All statistical tests were 2-sided. We identified 465 PCa patients (median age = 71 years) with a median follow-up of 60 days. Age, body mass index, cardiovascular comorbidity, and PCa clinical disease state adjusted overall survival (hazard ratio [HR] = 1.16, 95% confidence interval [CI] = 0.68 to 1.98, P = .59), hospitalization status (HR = 0.96, 95% CI = 0.52 to 1.77, P = .90), supplemental oxygenation (HR 1.14, 95% CI = 0.66 to 1.99, P = .64), and use of mechanical ventilation (HR = 0.81, 95% CI = 0.25 to 2.66, P = .73) were similar between ADT and non-ADT cohorts. Similarly, the addition of androgen receptor–directed therapy within 30 days of COVID-19 diagnosis to ADT vs ADT alone did not statistically significantly affect overall survival (androgen receptor–directed therapy: HR = 1.27, 95% CI = 0.69 to 2.32, P = .44). In this retrospective cohort of PCa patients, the use of ADT was not demonstrated to influence severe COVID-19 outcomes, as defined by hospitalization, supplemental oxygen use, or death. Age 70 years and older was statistically significantly associated with a higher risk of developing severe COVID-19 disease.

10 February 2024 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
DWDavid Wise
David Wise
RPRussell K. Pachynski
Russell K. Pachynski
SDSamuel R. Denmeade
Samuel R. Denmeade
RARahul Aggarwal
Rahul Aggarwal
JDJiehui Deng
Jiehui Deng
KWKwok-Kin Wong
Kwok-Kin Wong